Bradley S. Sherborne

Bradley S. Sherborne

Auto-generated profile, based on publicly available information

Bradley S. Sherborne

Pharmaron U.K., Integrated Drug Discovery Services, Pharmaron UK Ltd., Hoddesdon, United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2017 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
TLTai-Sung Lee
Tai-Sung Lee
YHYuan Hu
Yuan Hu
BSBrad Sherborne
Brad Sherborne
ZGZhuyan Guo
Zhuyan Guo
DYDarrin York
Darrin York

4 February 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
APAndrea Peier
Andrea Peier
LGLan Ge
Lan Ge
NBNicolas Boyer
Nicolas Boyer
JFJohn Frost
John Frost
RDRuchia Duggal
Ruchia Duggal
APAnthony Partridge
Anthony Partridge

18 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZHZiwei Hu
Ziwei Hu
ILInga V. Leus
Inga V. Leus
BCBrinda Chandar
Brinda Chandar
BSBradley S. Sherborne
Bradley S. Sherborne
QAQuentin P. Avila
Quentin P. Avila
ADAdam Duerfeldt
Adam Duerfeldt

20 August 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
FTFeven Tameire
Feven Tameire
PWPaulina Wojnarowicz
Paulina Wojnarowicz
CDCrissy Dudgeon
Crissy Dudgeon
KBKathryn T. Bieging-Rolett
Kathryn T. Bieging-Rolett
SFSho Fujisawa
Sho Fujisawa
ELEric S. Lightcap
Eric S. Lightcap
General control nonderepressible 2 (GCN2; EIF2AK4) is a serine–threonine kinase in the integrated stress response signaling pathway that initiates adaptive responses during nutrient stress conditions. Although pharmacologic inhibition of GCN2 under nutrient stress conditions induces apoptosis and inhibits tumor growth, GCN2 inhibition without nutrient stress has been reported to have no effect on tumor growth. By exploring an array of GCN2 inhibitors, we demonstrate that multiple agents in fact activate GCN2 in biochemical and cell-based assays at low concentrations and inhibit GCN2 at higher concentrations. Unexpectedly, it is this activation, and not inhibition, of the GCN2 pathway that is associated with decreased viability in vitro and tumor growth inhibition in vivo across multiple models. Knockdown and knockout experiments show that activation of the integrated stress response by GCN2-targeting agents is dependent on GCN2. ISRIB, a modulator of eIF2B, ablates the viability effect, demonstrating the dependence on translation initiation. Activating doses result in the induction of cleaved caspase 3 and cleaved PARP. In contrast, a nonactivating GCN2-targeting agent does not affect viability. These results provide a clearer understanding of the challenges and opportunities for the clinical development of compounds targeting GCN2.

2 January 2026
Verified
Other
Open access
FTFeven Tameire
Feven Tameire
PWPaulina Wojnarowicz
Paulina Wojnarowicz
CDCrissy Dudgeon
Crissy Dudgeon
KBKathryn T. Bieging-Rolett
Kathryn T. Bieging-Rolett
SFSho Fujisawa
Sho Fujisawa
ELEric S. Lightcap
Eric S. Lightcap
ATF4 activation is GCN2 dependent

2 January 2026
Verified
Other
Open access
FTFeven Tameire
Feven Tameire
PWPaulina Wojnarowicz
Paulina Wojnarowicz
CDCrissy Dudgeon
Crissy Dudgeon
KBKathryn T. Bieging-Rolett
Kathryn T. Bieging-Rolett
SFSho Fujisawa
Sho Fujisawa
ELEric S. Lightcap
Eric S. Lightcap
GCN2-targeting agents activate ATF4 activity and increase phosphorylation of eIF2α